Vaccines for Children (VFC) providers are now welcome to order nirsevimab (Beyfortus) as needed. Nirsevimab (Beyfortus), a monoclonal antibody immunization used to prevent RSV infection in infants and young children,\u202fcan be administered from October 1, 2025 to March 31, 2026.
<\/p>\n\n\n\n
Once we receive your nirsevimab orders, our team may adjust order quantities as needed to ensure equitable distribution among patient populations.
<\/p>\n\n\n\n
Eligibility, Dosage, & Administration<\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n Nirsevimab (Beyfortus) is administered as an intramuscular injection with a single-dose, pre-filled syringe.<\/p>\n\n\n\n <\/p>\n\n\n\n Indications<\/strong><\/p>\n\n\n\n Click here to view more information<\/strong><\/u><\/a>\u00a0about which children are at increased risk and should be vaccinated during their second season. <\/p>\n\n\n\n Storage & Handling<\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n Reporting Adverse Events<\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n Nirsevimab (Beyfortus) is the first immunoglobulin drug product to be included in the VFC program. If nirsevimab (Beyfortus) is administered:<\/p>\n\n\n\n Vaccines for Children (VFC) providers are now welcome to order nirsevimab (Beyfortus) as needed. Nirsevimab (Beyfortus), a monoclonal antibody immunization used to prevent RSV infection in infants and young children,\u202fcan be administered from October 1, 2025 to March 31, 2026. Once we receive your nirsevimab…<\/p>\n","protected":false},"author":22,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23,1,141,139],"tags":[],"class_list":["post-12777","post","type-post","status-publish","format-standard","hentry","category-medical-directors-notes","category-general","category-program-updates","category-vfc"],"_links":{"self":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/posts\/12777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/comments?post=12777"}],"version-history":[{"count":0,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/posts\/12777\/revisions"}],"wp:attachment":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/media?parent=12777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/categories?post=12777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/tags?post=12777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
Click here to view a flowchart<\/strong><\/u><\/a>\u00a0to aid providers in determining the appropriate dose of nirsevimab (Beyfortus) for patients.<\/p>\n\n\n\n\n
\n
\n